These emerging treatments, Retatrutide, represent a significant advancement in addressing type 2 diabetes and possibly other conditions . These drugs are categorized as GLP-1 pathway agonists , signifying they to emulate the endogenous GLP-1 hormone , boosting insulin release and reducing food in